Last reviewed · How we verify

Placebo matching with Abatacept

Bristol-Myers Squibb · FDA-approved active Small molecule

Placebo matching with Abatacept is a CTLA-4 fusion protein; T-cell costimulation inhibitor Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

At a glance

Generic namePlacebo matching with Abatacept
SponsorBristol-Myers Squibb
Drug classCTLA-4 fusion protein; T-cell costimulation inhibitor
TargetCD80, CD86
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Abatacept works by interrupting the second signal required for full T-cell activation. It consists of the extracellular domain of CTLA-4 fused to the Fc portion of IgG1, allowing it to bind CD80 and CD86 molecules on antigen-presenting cells. This prevents the interaction between these molecules and CD28 on T cells, effectively dampening adaptive immune responses in autoimmune conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo matching with Abatacept

What is Placebo matching with Abatacept?

Placebo matching with Abatacept is a CTLA-4 fusion protein; T-cell costimulation inhibitor drug developed by Bristol-Myers Squibb, indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

How does Placebo matching with Abatacept work?

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

What is Placebo matching with Abatacept used for?

Placebo matching with Abatacept is indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Systemic lupus erythematosus.

Who makes Placebo matching with Abatacept?

Placebo matching with Abatacept is developed and marketed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

What drug class is Placebo matching with Abatacept in?

Placebo matching with Abatacept belongs to the CTLA-4 fusion protein; T-cell costimulation inhibitor class. See all CTLA-4 fusion protein; T-cell costimulation inhibitor drugs at /class/ctla-4-fusion-protein-t-cell-costimulation-inhibitor.

What development phase is Placebo matching with Abatacept in?

Placebo matching with Abatacept is FDA-approved (marketed).

What are the side effects of Placebo matching with Abatacept?

Common side effects of Placebo matching with Abatacept include Infections (upper respiratory, urinary tract), Headache, Nausea, Dizziness, Hypertension.

What does Placebo matching with Abatacept target?

Placebo matching with Abatacept targets CD80, CD86 and is a CTLA-4 fusion protein; T-cell costimulation inhibitor.

Related